CD180 Recombinant Rabbit Monoclonal Antibody (105), Invitrogen™

Description

• This product is preservative free
• It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%)
• Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems
• The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits
• Then, individual clones are screened to select the best candidates for production
• The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire
• This antibody has specificity for Mouse CD180/RP105
• CD180 (RP105, Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family
• CD180 cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain
• CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells
• CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands
• Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size
• CD180 consists of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail
• The extracellular LRR is part of the cell surface receptor complex, RP105/MD-1
• Diseases associated with CD180 dysfunction include Kawasaki Disease in children and may play a role in rheumatic disease pathology.